These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38402253)

  • 21. Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review.
    Sukhram SD; Yilmaz G; Gu J
    Oxid Med Cell Longev; 2022; 2022():1061274. PubMed ID: 36160713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single and repeated ketamine treatment induces perfusion changes in sensory and limbic networks in major depressive disorder.
    Sahib AK; Loureiro JRA; Vasavada MM; Kubicki A; Joshi SH; Wang K; Woods RP; Congdon E; Wang DJJ; Boucher ML; Espinoza R; Narr KL
    Eur Neuropsychopharmacol; 2020 Apr; 33():89-100. PubMed ID: 32061453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression.
    Bottemanne H; Morlaas O; Claret A; Sharot T; Fossati P; Schmidt L
    JAMA Psychiatry; 2022 Nov; 79(11):1124-1132. PubMed ID: 36169969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma inflammatory cytokines and treatment-resistant depression with comorbid pain: improvement by ketamine.
    Zhou Y; Wang C; Lan X; Li H; Chao Z; Ning Y
    J Neuroinflammation; 2021 Sep; 18(1):200. PubMed ID: 34526064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression.
    Fagerholm ED; Leech R; Williams S; Zarate CA; Moran RJ; Gilbert JR
    Transl Psychiatry; 2021 May; 11(1):335. PubMed ID: 34052834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translating the immediate effects of S-Ketamine using hippocampal subfield analysis in healthy subjects-results of a randomized controlled trial.
    Höflich A; Kraus C; Pfeiffer RM; Seiger R; Rujescu D; Zarate CA; Kasper S; Winkler D; Lanzenberger R
    Transl Psychiatry; 2021 Apr; 11(1):200. PubMed ID: 33795646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ketamine and Attentional Bias Toward Emotional Faces: Dynamic Causal Modeling of Magnetoencephalographic Connectivity in Treatment-Resistant Depression.
    Gilbert JR; Galiano CS; Nugent AC; Zarate CA
    Front Psychiatry; 2021; 12():673159. PubMed ID: 34220581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.
    Nugent AC; Ballard ED; Gould TD; Park LT; Moaddel R; Brutsche NE; Zarate CA
    Mol Psychiatry; 2019 Jul; 24(7):1040-1052. PubMed ID: 29487402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study.
    Domany Y; Bleich-Cohen M; Tarrasch R; Meidan R; Litvak-Lazar O; Stoppleman N; Schreiber S; Bloch M; Hendler T; Sharon H
    Br J Psychiatry; 2019 Jan; 214(1):20-26. PubMed ID: 30246667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Ketamine on Brain Activity During Emotional Processing: Differential Findings in Depressed Versus Healthy Control Participants.
    Reed JL; Nugent AC; Furey ML; Szczepanik JE; Evans JW; Zarate CA
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2019 Jul; 4(7):610-618. PubMed ID: 30826253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hippocampal subfield volumes in treatment resistant depression and serial ketamine treatment.
    Zavaliangos-Petropulu A; McClintock SM; Joshi SH; Taraku B; Al-Sharif NB; Espinoza RT; Narr KL
    Front Psychiatry; 2023; 14():1227879. PubMed ID: 37876623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
    Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC; Chen LF; Li WC; Chen MH
    Int J Neuropsychopharmacol; 2023 May; 26(5):331-339. PubMed ID: 36966411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression.
    Chen MH; Lin WC; Wu HJ; Bai YM; Li CT; Tsai SJ; Hong CJ; Tu PC; Cheng CM; Su TP
    CNS Spectr; 2021 Aug; 26(4):362-367. PubMed ID: 32419678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression.
    Salloum NC; Fava M; Freeman MP; Flynn M; Hoeppner B; Hock RS; Cusin C; Iosifescu DV; Trivedi MH; Sanacora G; Mathew SJ; Debattista C; Ionescu DF; Papakostas GI
    Depress Anxiety; 2019 Mar; 36(3):235-243. PubMed ID: 30597688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.
    Lally N; Nugent AC; Luckenbaugh DA; Niciu MJ; Roiser JP; Zarate CA
    J Psychopharmacol; 2015 May; 29(5):596-607. PubMed ID: 25691504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression.
    Shiroma PR; Thuras P; Wels J; Albott CS; Erbes C; Tye S; Lim KO
    J Affect Disord; 2020 Dec; 277():470-477. PubMed ID: 32871534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?
    McIntyre RS; Lipsitz O; Lui LMW; Rodrigues NB; Lee Y; Ho RC; Subramaniapillai M; Gill H; Cha DS; Lin K; Teopiz KM; Nasri F; Mansur RB; Kratiuk K; Rosenblat JD
    J Affect Disord; 2021 Sep; 292():714-719. PubMed ID: 34161889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial.
    Murphy N; Tamman AJF; Lijffijt M; Amarneh D; Iqbal S; Swann A; Averill LA; O'Brien B; Mathew SJ
    Neuropsychopharmacology; 2023 Oct; 48(11):1586-1593. PubMed ID: 37076582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression.
    Rivas-Grajales AM; Salas R; Robinson ME; Qi K; Murrough JW; Mathew SJ
    Int J Neuropsychopharmacol; 2021 May; 24(5):383-391. PubMed ID: 33249434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.